ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
HSBC MSCI AC Far East Ex Japan ETF

HSBC MSCI AC Far East Ex Japan ETF (HMAF.GB)

0.00
0.00
(0.00%)
Cerrado 22 Enero 10:30AM
Realtime Data

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
-
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
-
Precio de Apertura
-
Hora
Última hora de negociación
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

HMAF.GB Últimas noticias

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 24 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 23 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 22 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 19 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 18 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 17 January 2024 Fund: HSBC MSCI AC FAR Share EAST EX Redeemed JAPAN since Ex UCITS Valuation Shares Previous NET Asset NAV per Dividend ETF Date ISIN Code in...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 16 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 15 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 12 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

HSBC ETFs MSCI AC FarEastExJapan $ Net Asset Value(s)

HSBC ETFs MSCI AC FarEastExJapan $ 11 January 2024 Share Fund: HSBC Redeemed MSCI AC FAR since EAST EX JAPAN Valuation Shares in Previous NET Asset NAV per Ex Dividend UCITS ETF Date ISIN Code...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000SP
40000000SP
120000000SP
260000000SP
520000000SP
1560000000SP
2600000000SP

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.07M
ASSTAsset Entities Inc
US$ 1.36
(51.11%)
121.67M
STAIScanTech AI Systems Inc
US$ 2.12
(44.22%)
51.68M
JYDJayud Global Logistics Ltd
US$ 3.53
(42.91%)
1.27M
NTRBNutriband Inc
US$ 7.39
(41.84%)
3.88M
STFSStar Fashion Culture Holdings Ltd
US$ 2.62
(-80.61%)
30.25M
HEPAHepion Pharmaceuticals Inc
US$ 0.135
(-58.05%)
39.89M
STBXStarBox Group Holdings Ltd
US$ 0.6201
(-36.50%)
1.63M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 93.51
(-35.73%)
1
JUNSJupiter Neurosciences Inc
US$ 3.61
(-33.39%)
6.87M
IPAImmunoPrecise Antibodies Ltd
US$ 0.6446
(30.75%)
296.43M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.3191
(33.57%)
229.11M
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
NVDANVIDIA Corporation
US$ 147.07
(4.43%)
216.62M
RGTIRigetti Computing Inc
US$ 13.89
(-0.64%)
154.54M
Hardazoak Hardazoak 2 minutos hace
Current Aabbg works fine, wallet works fine. New aabb wallet 2.0 with AI and moonpay exchange integrated coming. Stop with the lies gitreal, only you are believing your own lies.
AABB
KPIFF-LDDFF KPIFF-LDDFF 3 minutos hace
KPIFF
wadegarret wadegarret 3 minutos hace
Novice- AI stocks have mostly done their thing

I don't believe Stargate will add all that much to boost valuations further. I mean NVDA already sells for over a 30 something PE going forward, CRDO sells for an 85 PE going forward, CRWD sells for around an 80 PE going forward, PLTR
AES CRDO CRWD
PEACHMAN PEACHMAN 3 minutos hace
The exact opposite of what you say is true.LOLOLOLOL!!!!! I OWN you, kitty. Heart, mind, body and soul!! You fall into traps, you copy verbatim my posts. Have you ever had an independent thought in your life?

https://investorshub.advfn.com/uimage/uploads/2025/1/22/sdlmono_panther.pn
IFUS
pinhigh pinhigh 4 minutos hace
Well done video gimmee! RRX!
BIEL
Orange Cassidy Orange Cassidy 5 minutos hace
The Jared "whisperer" is still here in emoji form on every post. He has not gone anywhere. As it stands the mills are abandoned and this is still a sham. "Whats not to like?"
NBRI
bas2020 bas2020 5 minutos hace
Any shorting after approval will be total manipulation by the corrupt cabal... your bosses. Hopefully, we'll have MTD denial prior with a cease and desist order to go with it... to cut ya all off at the knees. 💥
NWBO
hssbwwmp hssbwwmp 6 minutos hace
Yes, I've seen them cite those factors in their reports as well as being flexible to adapt to them. So, it would seem that if AXXA was still able to grow revenue and reduce debt despite those factors, then the PPS should not have continued this long downtrend, correct? Something still is not comp
AXXA
RichieBoy RichieBoy 6 minutos hace
Minute 28 - Minute 40 is on AI

Keep in mind this is acutely political. So you'll be left wondering about this side of AI and oh that part of AI why aren't they important. They are important of course, but never before to date will you have seen such intense focus on this one facet.
AFFU
boarddork boarddork 8 minutos hace
That’s a lot of push pins and zig zag strings to make that ultimate conclusion.
COOP
weedtrader420 weedtrader420 8 minutos hace
BITCOIN XRP TRIUMPH MAGIC POWER $120,000 TARGET
BTCUSD
janice shell janice shell 9 minutos hace
She's one of the very few who actually deserves a pardon.
Hoskuld Hoskuld 10 minutos hace
This is not really true Boi - although I can imagine that logically it should be true. But, no 2 companies run their trials the same way. Usually. this is deliberate. The FDA cannot evaluate them the same way, as a result. The guidelines are NOT requirements. They are simply suggestions.
AVXL
StayHumble StayHumble 11 minutos hace
wow💹100% Xpert SHORT interest💹significant evidence of SHORTS💹💹 huzzah!!!
HMBL
WALL STREET KID WALL STREET KID 11 minutos hace
$AMC 5B SWAPS EXPIRING! SHORTS AT RISK! Short Squeeze Update

https://youtu.be/eUD6PpQ-Oxw?si=QpOWsGLt0b2Qu2s6
AMC
vinmantoo vinmantoo 14 minutos hace
Jq1234, give Bluesky a try. It looks a lot like Twitter did but doesn’t have a controlling algorithm.
WhAtEvA1 WhAtEvA1 14 minutos hace
With 18 indications trial starting in India well ahead of US trials (and if proven successful) it won't take long when Vivos valuations will be trading forward. IMHO of course. It is worth bios do when efficacy data is strong and potential of approval in the public interest outweighs the risks.
RDGL
glens0 glens0 15 minutos hace
$CTOR Not to many shares left in the market. Should go up real fast when good news comes out. And it should be soon.
Total Insider Shares Held 64.72M
Citius Oncology Annual Shares Outstanding
(Millions of Shares)
2024 68M
CTOR
Zorch305 Zorch305 16 minutos hace
Whats 305
RNVA
theorysuit theorysuit 17 minutos hace
You keep pointing to this journal as if that leads to approval. I think i told you this, this journal was meant to explain this garbage trial.....Pointing to the scoreboard. Any approvals? Over 20 years since this trial was started, 6 years since it has ended, and 4.5 years since data lock. NO
NWBO
WHITTENHALLJR WHITTENHALLJR 17 minutos hace
Yes I bet it 2x better then before strap in stock-nuts
CLHI

Su Consulta Reciente

Delayed Upgrade Clock